Rheumatic And Musculoskeletal Diseases
Rheumatic disease activity at time of COVID-19 vaccination drives subsequent flare risk
Higher disease activity and medication reduction at COVID-19 vaccination increase the risk for subsequent flares in patients with rheumatic and musculoskeletal diseases, according to data published in Annals of the Rheumatic Diseases.
More than half of patients with rheumatic, musculoskeletal disease use OTC supplements
More than 54% of patients with rheumatic and musculoskeletal diseases report daily use of over-the-counter supplements, with “considerable” intake alongside pain relievers, according to data published in Rheumatology Advances in Practice.
New EULAR guidance on patient research partners aims to overcome ‘tokenistic’ approaches
All rheumatology research projects should include at least two patient partners, supported by a designated coordinator, who collaborate as equals with researchers, according to new EULAR recommendations.
New EULAR trial center network, databases ‘crucial’ to advancing RMD care quality
A new trial center network and two major data collection projects are among recent EULAR initiatives for improved care of patients with rheumatic and musculoskeletal diseases, according to a speaker at the EULAR 2024 Congress.
EULAR launches first patient-reported survey on rheumatic, musculoskeletal disease impacts
EULAR has initiated a survey that will collect data directly from patients on the impact and outcomes of rheumatic and musculoskeletal diseases, according to a statement released during the EULAR 2023 Congress.
Future of apps for patient self-management uncertain, may rely on specialized functions
The longevity of apps and programs aimed at helping patients achieve self-management remains uncertain, according to speakers at a debate session during the EULAR 2023 Congress.
EULAR launches RheumaFacts, a ‘unique data repository’ for RMDs across Europe
EULAR has launched RheumaFacts, a novel resource for local and national data regarding rheumatic and musculoskeletal diseases in Europe, according to a presenter at the EULAR 2023 Congress.
‘Disentangling’ disease, treatments and comorbidities can reduce mortality in RMDs
Managing comorbidities is critical to minimizing deaths in patients with rheumatic and musculoskeletal diseases, according to data presented at EULAR 2023 Congress.
EULAR president: Inclusivity, innovation at heart of EULAR’s mission
Ensuring equal opportunity for patients to receive care, and for practitioners to grow in their careers, is at the heart of EULAR’s mission for 2023 and beyond, according to opening remarks at the EULAR 2023 Congress.
EULAR: Telehealth useful for disease monitoring; barriers to access exist
Although telehealth can be useful in treating patients with rheumatic diseases, diagnoses should be established in face-to-face visits, according to new EULAR points to consider.